comparemela.com

Ret Inhibitor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rigel takes on US marketing of Blueprint s Gavreto

Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights.

Blueprint medicines corpRoche holdingRigel pharmaceuticals incBlueprint medicinesRigel pharmaceuticalsBlueprint medicines corpRigel pharmaceuticals incRoche holding agNon small cell lung cancerDeals andm amp aRet inhibitorMedullary thyroid cancer

#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute medicine incMedullary thyroid cancerRet inhibitorRet mutant thyroid cancerThyroid cancer

Sequencing Throughout Multiple Lines of Therapy in RR DTC

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Treatment approachesSequencing strategiesDifferentiated thyroid cancerThroughout multiple linesThyroid cancerDtc cancerRet fusionsRet expressionRet inhibitorAcquired resistanceMultikinase inhibitorsSequencing therapySequencing treatment

Patient Scenario 3: Treating RR DTC With an Identified RET Fusion

Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.

Francis wordenTreatment approachesSequencing strategiesDifferentiated thyroid cancerThyroid cancerDtc cancerRet fusionsRet expressionCombination therapyRet inhibitorCns disease

Optimizing Use of RET Inhibitors in Patients With RR DTC

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Treatment approachesSequencing strategiesDifferentiated thyroid cancerPatients withThyroid cancerDtc cancerRet fusionsRet expressionRet inhibitorAdverse eventsDrug adverse eventsHematologic aesHematologic adverse events

vimarsana © 2020. All Rights Reserved.